Half-life: 6.7 days
Main emission lines: 55keV, 112keV, 208keV.
Where detected
Lutetium-177 (Lu-177) is a medical isotope used in targeted radionuclide therapy for treating neuroendocrine tumours and prostate cancer.
In the US, Lu-177 dotatate is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
In the EU, Lu-177 oxodotreotide is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults
